iifl-logo-icon 1

Ishita Drugs & Industries Ltd Share Price

68.88
(-2.01%)
Jul 22, 2024|09:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open0
  • Day's High0
  • 52 Wk High98.37
  • Prev. Close70.29
  • Day's Low0
  • 52 Wk Low56
  • Turnover (lac)0
  • P/E28.12
  • Face Value10
  • Book Value33.17
  • EPS2.5
  • Mkt. Cap (Cr.)20.6
  • Div. Yield0
No Records Found

Ishita Drugs & Industries Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

0

Prev. Close

70.29

Turnover(Lac.)

0

Day's High

0

Day's Low

0

52 Week's High

98.37

52 Week's Low

56

Book Value

33.17

Face Value

10

Mkt Cap (₹ Cr.)

20.6

P/E

28.12

EPS

2.5

Divi. Yield

0

Ishita Drugs & Industries Ltd Corporate Action

23 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

28 Aug 2023

12:00 AM

AGM

Announcement Date: 28 Aug, 2023

arrow

28 Aug 2023

12:00 AM

BookCloser

arrow

Ishita Drugs & Industries Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ishita Drugs & Industries Ltd SHAREHOLDING SNAPSHOT

22 Jul, 2024|09:10 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 49.42%

Foreign: 0.00%

Indian: 49.42%

Non-Promoter- 50.57%

Institutions: 0.00%

Non-Institutions: 50.57%

Custodian: 0.00%

Share Price

Ishita Drugs & Industries Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

2.99

2.99

2.99

2.99

Preference Capital

0

0

0

0

Reserves

6.18

5.61

4.8

3.97

Net Worth

9.17

8.6

7.79

6.96

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

13.94

14.83

6.84

6.43

yoy growth (%)

-5.95

116.75

6.26

-9.32

Raw materials

-10.28

-11.44

-4.73

-3.97

As % of sales

73.74

77.16

69.16

61.68

Employee costs

-1.09

-1.09

-0.79

-0.69

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

1.05

0.71

0.32

0.25

Depreciation

-0.14

-0.17

-0.13

-0.13

Tax paid

-0.22

-0.16

-0.07

-0.07

Working capital

2.9

-1.04

-0.26

-1.4

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

-5.95

116.75

6.26

-9.32

Op profit growth

20.26

92.91

9.73

31.17

EBIT growth

45.07

71.67

44.5

21.42

Net profit growth

51.63

120.78

35.8

33.01

View Ratios

No Record found

Ishita Drugs & Industries Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,568.45

123.313,76,323.69867.60.865,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,520.1

76.171,19,994.455310.662,259507.93

Cipla Ltd

CIPLA

1,485.15

32.291,19,928.541,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,144.6

33.511,15,173.541,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,639.05

25.851,10,759.071,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ishita Drugs & Industries Ltd

Management

Register Office

Registrar Office

Managing Director

Jagdish Agrawal

Director

Govind Gupta

Non Executive Director

Abha Agrawal

Director

Niranjan Agrawal

Director

Arvind Sapkal

Company Sec. & Compli. Officer

Srushti Pandya

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Ishita Drugs & Industries Limited was incorporated in Feb.92 by Jagdish Agarwal. The Company is engaged in the manufacture of various Activa Pharma Ingredients, drug intermediates, fine chemicals and excipient. It has a state-of-art manufacturing facility, in terms of reaction capabilities, quality control and environmental safety. The plant has been designed and constructed to meet GMP norms.The genesis of the Ishita Group in 1992 was the result of the entrepreneurial spirit of Mr. Jagdish Agrawal, who set up a reactive dye manufacturing unit in Ahmedabad. Buoyed by the growth of its first Venture, the Group made its maiden foray in the pharma sector in 1981 by setting up a small Bulk drugs plant at Surendranagar in Gujarat, to cater to the need of Pharma industry for Quality Products. The Bulk Drugs Industry at that point of time was highly dependent on costly imports and the growth was not achievable. The Company gradually formed a vertically integrated industry chain covering Drug Intermediates, Active Pharma Ingredients (APIs), excipients and finished dosage forms. The Group has 3 manufacturing facilities located in Gujarat, 2 for APIs and drug intermediates (at Ahmedabad and Surendranagar) and 1 for finished pharmaceutical formulations (at Mehsana).Thereafter, the Company set up a project to manufacture bulk drugs at Sanand, in the Ahmedabad district of Gujarat with an installed capacity of 408 tpa. Commercial production commenced in Jan.95. It established an in-house R
Read More

Company FAQs

What is the Ishita Drugs & Industries Ltd share price today?

Down Arrow

The Ishita Drugs & Industries Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹68.88 today.

What is the Market Cap of Ishita Drugs & Industries Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ishita Drugs & Industries Ltd is ₹20.60 Cr. as of 22 Jul ‘24

What is the PE and PB ratio of Ishita Drugs & Industries Ltd?

Down Arrow

The PE and PB ratios of Ishita Drugs & Industries Ltd is 28.12 and 2.12 as of 22 Jul ‘24

What is the 52 Week High and Low of Ishita Drugs & Industries Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Ishita Drugs & Industries Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ishita Drugs & Industries Ltd is ₹56 and ₹98.37 as of 22 Jul ‘24

What is the CAGR of Ishita Drugs & Industries Ltd?

Down Arrow

Ishita Drugs & Industries Ltd's CAGR for 5 Years at 29.91%, 3 Years at 20.17%, 1 Year at -6.40%, 6 Month at -7.39%, 3 Month at -0.23% and 1 Month at 9.52%.

What is the shareholding pattern of Ishita Drugs & Industries Ltd?

Down Arrow

The shareholding pattern of Ishita Drugs & Industries Ltd is as follows:
Promoters - 49.42 %
Institutions - 0.00 %
Public - 50.58 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.